ZyGem

New firm MicroGem picked up the assets of bankrupt ZyGem and its affiliate MicroLab, seeing promise in the firm's extremophile enzyme collection.

ZyGem LLC, a former US subsidiary of New Zealand-based biotech firm ZyGem Limited, is no longer in business after a group of former employees and contractors earlier this year filed a petition with a federal court to force the company into Chapter 7 bankruptcy for debts owed,

Transgenomic said this week that Paul Kinnon has been named president, CEO, and a director of the company, replacing Craig Tuttle.

Life Technologies said this week that it has become the exclusive worldwide distributor for LGC Forensics' recently launched ParaDNA platform, a portable DNA testing system designed to determine the quality of human DNA more quickly and efficiently than existing methods.

This article has been updated from a previous version to provide information regarding the name of ZyGem's DNA testing platform.

Researchers from the Center for Applied NanoBioscience and Medicine at the University of Arizona have published a paper describing a number of improvements to their fully integrated, microfluidic forensic device for rapid multiplex PCR-based DNA analysis.

NEW YORK (GenomeWeb News) – ZyGem today said that it has entered into an agreement with Quanta BioSciences to incorporate its enzymatic RNA-extraction technology into Quanta's quantitative PCR reagent kits.

NEW YORK (GenomeWeb News) – ZyGem today said it has entered into a non-exclusive distribution deal with Tataa Biocenter.
The deal is for the distribution of ZyGem's DNA and RNA extraction products in Sweden and other selected countries. Other details were not disclosed.

ZyGem said today that it has signed an OEM agreement with Saudi Diagnostics, which will market ZyGem's DNA and RNA extraction kits for a variety of research applications.

Pages

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.